



Change in Age Indication for Flucelvax Quadrivalent

Lisa Grohskopf, MD, MPH

Influenza Division, NCIRD, CDC

Advisory Committee on Immunization Practices

October 20, 2021

Acknowledgements

Influenza Division

Elif Alyanak
Noreen Alabi
Lenee Blanton
Lynnette Brammer
Alicia Budd
Jessie Chung
Vivien Dugan
Jill Ferdinands
Brendan Flannery
Alicia Fry
Krista Kniss
Manish Patel
Melissa Rolfes
Tim Uyeki

Immunization Safety Office

Karen Broder
Frank Destefano
Anamika Dua
Penina Haber
Tom Shimabukuro

Immunization Services Division

Sam Graitcer
Andrew Kroger
Amy Parker Fiebelkorn
Jeanne Santoli

Change in Age Indication for Flucelvax Quadrivalent

Cell culture-based inactivated influenza vaccine:

- Age indication changed from ≥ 4 years to ≥ 2 years (approved by FDA in March, 2021).
- On October 14, 2021, FDA approved for ages ≥ 6 months.
- Data presented at June 2021 ACIP meeting
 - Randomized trial of immunogenicity and safety compared to licensed egg-based quadrivalent inactivated influenza vaccine (Afluria Quadrivalent), among 2,402 children ages 6 to ≤ 47 months
 - Flucelvax Quadrivalent: 0.5 mL/dose
 - Afluria Quadrivalent: 0.25 mL/dose for 6 through 35 months;
0.5 mL/dose for 36 through 47 months.
 - Prespecified noninferiority criteria met for Geometric Mean Titer (GMT) ratios and difference in seroconversion rates for all four viruses
 - Rates of solicited and unsolicited adverse events similar between groups

Influenza Vaccines by Age Indication, United States, 2021–22 Influenza Season

Vaccine type		0 through 6 months	6 through 23 months	2 through 17 years	18 through 49 years	50 through 64 years	≥65 years
IIV4s	Standard-dose, unadjuvanted inactivated (IIV4)	Not approved for age group	Eggbased Afluria Quadrivalent Fluarix Quadrivalent FluLaval Quadrivalent Fluzone Quadrivalent				
	Cell culture-based inactivated (cIIV4)		Not eggbased Flucelvax Quadrivalent				
	Adjuvanted inactivated (aIIV4)	Not approved for age group					Eggbased Fluad Quadrivalent
	High-dose inactivated (HD-IIV4)	Not approved for age group					Eggbased Fluzone High-Dose Quadrivalent
RIV4	Recombinant (RIV4)	Not approved for age group			Not eggbased Flublok Quadrivalent		
LAIV4	Live attenuated (LAIV4)	Not approved for age group		Eggbased FluMist Quadrivalent	Not approved for age group		

IIV4=quadrivalent inactivated influenza vaccine RIV4=quadrivalent recombinant influenza vaccine LAIV4=quadrivalent live attenuated influenza vaccine



Not approved for age group



Eggbased



Not eggbased

All vaccines expected for 2021–22 are quadrivalent (i.e., contain hemagglutinin derived from four viruses: one influenza A(H1N1), one influenza A(H3N2), one influenza B/Victoria and one influenza B/Yamagata).

Inactivated Influenza Vaccines (IIV4s) for Children 6 through 35 months

- Five IIV4s are now approved for this age group
- Dose volumes vary:
 - Fluarix Quadrivalent 0.5 mL/dose
 - FluLaval Quadrivalent 0.5 mL/dose
 - Flucelvax Quadrivalent 0.5 mL/dose
 - Afluria Quadrivalent 0.25 mL/dose
 - Fluzone Quadrivalent 0.25 mL/dose *or* 0.5 mL/dose

Change in Age Indication for Flucelvax Quadrivalent

Will be reflected in

- Online version of Table of available vaccines for 2021-22 (<https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm>)
- Brief summary of ACIP recommendations

Thank you!

A decorative horizontal bar at the bottom of the slide, composed of several colored rectangular segments: a long grey segment on the left, followed by purple, olive green, maroon, yellow, and blue segments on the right.